Compare DRVN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRVN | RAPP |
|---|---|---|
| Founded | 1972 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2020 | 2024 |
| Metric | DRVN | RAPP |
|---|---|---|
| Price | $13.05 | $36.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $18.33 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.5M | 288.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.70 | 24.34 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $1,862,438,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.53 | N/A |
| P/E Ratio | $15.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.80 | $10.57 |
| 52 Week High | $19.74 | $42.27 |
| Indicator | DRVN | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 47.28 |
| Support Level | $12.49 | $25.48 |
| Resistance Level | $13.54 | $41.18 |
| Average True Range (ATR) | 0.59 | 1.93 |
| MACD | -0.11 | -0.31 |
| Stochastic Oscillator | 27.69 | 30.01 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.